唑来膦酸注射液治疗骨质疏松症疗效观察

Observation of curative effect of Zoledronic acid injection on treatment of patients with osteoporosis

目的:探讨唑来膦酸钠注射液(密固达)治疗原发性骨质疏松症的效果。方法:将122例骨质疏松症患者患者按照随机配对原则分为治疗组和对照组。对照组(n=61)给予钙尔奇D片(含有钙和维生素D3)1片,1次·d-1,疗程为1年;治疗组(n=61)给予唑来膦酸钠注射液5 mg静脉点滴,1次。对两组患者治疗前和治疗1年后血钙、血磷和碱性磷酸酶(ALP)的变化及腰椎、股骨颈、髋部的骨密度和临床疗效进行比较。结果:治疗后1年,两组患者血钙、血磷及碱性磷酸酶(ALP)与治疗前比较,除ALP外,差异均无统计学意义(P>0.05);治疗组和对照组腰椎、股骨颈、大转子的骨密度比较,差异均有统计学意义(P<0.05)。治疗组总有效率为(显效+有效)为96.72%(59/61),对照组总有效率为81.97%(50/61),两组间差异有统计学意义(P<0.05)。结论:唑来膦酸钠注射液治疗骨质疏松症疗效显著,安全、依从性好,是治疗骨质疏松症理想药物选择。

Objective: To explore the curative effect of Zoledronic acid injection in treatment of primary osteoporosis. Methods: One hundred twenty-two patients with osteoporosis were divided into treatment group and control group in accordance with the principle of random pairing. Control group( n = 61) was given Caltrate( 1 piece,one time / one day) for 1 year,treatment group was given Zoledronic acid injection( 5 mg). Blood calcium, phosphorus,the change of blood alkaline phosphatase( ALP) and bone density of lumbar,femoral neck,hip and clinical curative effect were compared between the two groups before and 1 year after treatment. Results: One year after treatment,in addition to the ALP,blood calcium,phosphorus of the patients had no statistically significant difference( all P > 0. 05),bone density of lumbar,femoral neck,hip had statistically significant difference( all P < 0. 05). Total effective rate( powerfully + effective) of treatment group was 96. 72%( 59 /61),effective rate of control group was 81. 97%( 50 /61). There was statistically significant difference( P < 0. 05). Conclusion: Curative effect of Zoledronic acid for treatment of osteoporosis is distinct,safety,compliance and it is ideal choice for the treatment of osteoporosis.